Genetic Analysis of CYP2C9 with Reference to Drug Response in Epilepsy Patients of Pakistan

Overview

Journal Genet Res (Camb)

Specialty Genetics

Date 2022 Feb 9

PMID 35136381

Authors

Hafsa Maqbool

Tayyaba Saleem

Nadeem Sheikh

Aqsa Ashfaq

Affiliations

Soon will be listed here.

Abstract

Epilepsy is a major global issue. Epilepsy patients are treated with AED (antiepileptic drugs). Interindividual variability in drug response has been documented in several studies. The resistance to drug response may be attributed to genetic polymorphism. The current study was undertaken to investigate the CYP2C9 gene polymorphism associated with antiepileptic drug (AED) resistance in the Pakistani population. The current study included 337 individuals including 100 control subjects, 110 drug-resistant subjects, and 127 drug responders. Genomic DNA was isolated from blood, and amplification of rs1799853 (430C > T) and rs1057910 was carried out by polymerase chain reaction. Genotypes of CYP2C9 SNPs were determined by Sanger's sequencing. Astounding results were observed in the current study that none of the well-known reported SNPs of CYP2C9 was found in our Pakistani cohorts. However, a novel missense variant (c.374G > A) was found only in drug-resistant patients of the current study. According to the analysis performed by PolyPhen-2, it was observed that this nonsynonymous substitution is likely to be pathogenic. The results of our study demonstrated that rs1799853 and rs1057910 may be involved in drug resistance in the Pakistani population. However, some other variants on CYP2C9 may play a critical role in AED resistance that needs to be explored.

References

Lazarowski A, Czornyj L . Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions. Drug Metabol Drug Interact. 2011; 26(1):21-6. DOI: 10.1515/DMDI.2011.006. View

Coe B, Girirajan S, Eichler E . The genetic variability and commonality of neurodevelopmental disease. Am J Med Genet C Semin Med Genet. 2012; 160C(2):118-29. PMC: 4114147. DOI: 10.1002/ajmg.c.31327. View

Grover S, Gourie-Devi M, Baghel R, Sharma S, Bala K, Gupta M . Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics. 2010; 11(7):927-41. DOI: 10.2217/pgs.10.62. View

Lin J, Lu A . Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1998; 49(4):403-49. View

Suvichapanich S, Jittikoon J, Wichukchinda N, Kamchaisatian W, Visudtibhan A, Benjapopitak S . Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children. J Hum Genet. 2015; 60(8):413-7. DOI: 10.1038/jhg.2015.47. View

Kumari R, Lakhan R, Garg R, Kalita J, Misra U, Mittal B . Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J Hum Genet. 2011; 17 Suppl 1:S32-40. PMC: 3125053. DOI: 10.4103/0971-6866.80357. View

Lakhan R, Kumari R, Singh K, Kalita J, Misra U, Mittal B . Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy. Indian J Med Res. 2011; 134:295-301. PMC: 3193709. View

Sanchez-Diz P, Estany-Gestal A, Aguirre C, Blanco A, Carracedo A, Ibanez L . Prevalence of CYP2C9 polymorphisms in the south of Europe. Pharmacogenomics J. 2009; 9(5):306-10. DOI: 10.1038/tpj.2009.16. View

Scordo M, Aklillu E, Yasar U, Dahl M, Spina E, Ingelman-Sundberg M . Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol. 2001; 52(4):447-50. PMC: 2014581. DOI: 10.1046/j.0306-5251.2001.01460.x. View

10.

Green M, Sambrook J . Isolation of High-Molecular-Weight DNA Using Organic Solvents. Cold Spring Harb Protoc. 2017; 2017(4):pdb.prot093450. DOI: 10.1101/pdb.prot093450. View

11.

Makowska M, Smolarz B, Brys M, Forma E, Romanowicz H . An association between the rs1799853 and rs1057910 polymorphisms of CYP2C9, the rs4244285 polymorphism of CYP2C19 and the prevalence rates of drug-resistant epilepsy in children. Int J Neurosci. 2020; 131(12):1147-1154. DOI: 10.1080/00207454.2020.1781110. View

12.

Manford M . Recent advances in epilepsy. J Neurol. 2017; 264(8):1811-1824. PMC: 5533817. DOI: 10.1007/s00415-017-8394-2. View

13.

Ghosh C, Hossain M, Solanki J, Najm I, Marchi N, Janigro D . Overexpression of pregnane X and glucocorticoid receptors and the regulation of cytochrome P450 in human epileptic brain endothelial cells. Epilepsia. 2017; 58(4):576-585. PMC: 5386820. DOI: 10.1111/epi.13703. View

14.

Ke X, Cheng Y, Yu N, Di Q . Effects of carbamazepine on the P-gp and CYP3A expression correlated with PXR or NF-κB activity in the bEnd.3 cells. Neurosci Lett. 2018; 690:48-55. DOI: 10.1016/j.neulet.2018.10.016. View

15.

Franco V, Perucca E . CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opin Drug Metab Toxicol. 2015; 11(8):1269-79. DOI: 10.1517/17425255.2015.1053463. View

16.

Udani V . Pediatric epilepsy -- an Indian perspective. Indian J Pediatr. 2005; 72(4):309-13. View

17.

Rosemary J, Surendiran A, Rajan S, Shashindran C, Adithan C . Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Indian J Med Res. 2006; 123(5):665-70. View

18.

Emich-Widera E, Likus W, Kazek B, Niemiec P, Balcerzyk A, Sieron A . CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents. Biomed Res Int. 2013; 2013:526837. PMC: 3747339. DOI: 10.1155/2013/526837. View

19.

Al-Mohizea A, Alkharfy K, Bagulb K, Alghamdi A, Al-Jenoobi F, Al-Muhsen S . Genetic variability and haplotype profile of MDR1 in Saudi Arabian males. Mol Biol Rep. 2012; 39(12):10293-301. DOI: 10.1007/s11033-012-1906-3. View

20.

Pierzchala K . [Pharmacoresistant epilepsy - epidemiology and current studies]. Neurol Neurochir Pol. 2010; 44(3):285-90. DOI: 10.1016/s0028-3843(14)60043-8. View